Understanding how to optimize antibiotic dosing for severe pneumonia
Official title: Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia
Funded at Midwestern University · NIH-10868657 · Data updated 2026-11-12
This study is working to make treatments for hospital-acquired pneumonia more effective, especially for patients with antibiotic-resistant infections, by figuring out the best doses of common antibiotics to use based on how each person processes the medication.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Midwestern University NIH-funded |
| Lab location | 1 site (Downers Grove, United States) |
| Project start | July 11, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $669,238 |
| NIH project number | 5R01AI158530-03 |
| Project ID | NIH-10868657 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are critically ill patients diagnosed with hospital-acquired pneumonia caused by antibiotic-resistant pathogens.
✕Less likely to help
Patients with pneumonia not caused by antibiotic-resistant bacteria or those who are not critically ill may not benefit from this research.
What this research studies
This research focuses on improving the treatment of hospital-acquired pneumonia (HAP) caused by antibiotic-resistant bacteria. It aims to develop precision dosing strategies for beta-lactam antibiotics, which are commonly used but often ineffective due to variability in how patients metabolize these drugs, especially in critically ill individuals. By utilizing existing data and samples from a previous research initiative, the study will create robust pharmacokinetic models to better understand how to achieve effective drug levels in patients. This approach seeks to reduce treatment failures and mortality rates associated with HAP.
Why it matters
Potential benefit: If successful, this research could lead to more effective antibiotic treatments for patients suffering from severe pneumonia, potentially reducing mortality rates.
How similar studies have gone: Previous research has shown promise in developing precision dosing strategies for antibiotics, indicating that this approach could be effective.
Where this research is happening
-
Midwestern University
Downers Grove, United States Active
Researchers
- Principal investigator: Rhodes, Nathaniel James — Midwestern University
- Study coordinator: Rhodes, Nathaniel James
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Endothelial inflammation memory after sepsis and pneumonia
A scientist is studying how blood vessel cells “remember” sepsis and why survivors get worse when they catch pneumonia, with the goal of finding better ways to reduce organ damage.
-
Bacterial Biofilm Therapy with a Human Antibody to Help Antibiotics Work Better
A human antibody drug is being studied to disrupt bacterial biofilms and help standard antibiotics clear infections, especially around implants and catheters, in adults.
-
A tissue slice model to test treatments for Pneumocystis pneumonia in people with HIV/AIDS
Researchers are creating a lung-slice model to study Pneumocystis jirovecii pneumonia and test potential treatments using tissue from infected, immunosuppressed mice to better predict what might help people with HIV/AIDS.
-
Measuring respiratory and gut bacteria to predict pneumonia treatment failure
A project to understand how bacterial load in the lungs and gut changes during and after antibiotics for hospital-acquired and ventilator-associated pneumonia, with the goal of predicting which patients might fail treatment.
-
Better tests and treatments for Pneumocystis (PCP) pneumonia
Developing more accurate tests and safer treatment options for people with weakened immune systems who get Pneumocystis pneumonia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.